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Glutathione S-transferase polymorphisms and skin cancer after 40% 20 years after transplantation [reviewed in 1]. The
renal transplantation. majority of tumors are squamous cell carcinomas (SCCs)
Background. Susceptibility to skin cancer after transplanta- [2, 3], but the frequencies of basal cell carcinomas (BCCs)tion is multifactorial, and risk factors include skin type, sun
and malignant melanoma are also increased [4, 5]. Skinexposure, and level of immunosuppression. A major mechanism
tumors frequently occur at multiple sites [2, 6] and areof carcinogenesis is ultraviolet radiation-induced free radical
damage, and genetically determined ability to metabolize free more aggressive in transplant recipients than in the gen-
radicals may also predispose to skin cancer. The glutathione eral population [7]. Susceptibility to skin cancer after
S-transferase enzymes play a major role in limiting the toxic transplantation is multifactorial, and the major risk fac-effects of reactive oxygen species, and this study was designed
tors are skin type, pretransplant and post-transplant sunto determine whether polymorphisms in these enzymes are
exposure, duration and type of systemic immunosuppres-associated with skin cancers in renal transplant recipients.
Methods. Two hundred twenty-two long-term survivors of sion, and human papillomavirus (HPV) infection [5, 8].
renal transplantation were examined for polymorphisms in the In “high-risk” areas such as Australia, the combination
GSTM1, GSTT1, and GSTP1 genes, using a unified polymerase of intense ultraviolet (UV) light exposure and immuno-chain reaction with sequence specific primers (PCR-SSP) geno-
suppressive therapy results in a frequency of SCC attyping method.
least 20 times higher in renal transplant recipients thanResults. The GSTP1*C allele was associated with the devel-
opment of squamous cell carcinomas (SCCs; P 5 0.01). No in nonimmunosuppressed Caucasoid individuals [9].
associations of the GSTM1 null genotype or the GSTT1 null One of the mechanisms by which UV light mediates
genotype were identified, and the development of basal cell its carcinogenic effect is by stimulating the productioncarcinomas was not associated with any GST polymorphism
of free radicals, which trigger both DNA damage andstudied.
abnormal cytoplasmic signal transduction [10]. The injuri-Conclusions. These results indicate that genetic variation in
enzymes involved in free radical metabolism in the skin are ous effect of reactive oxygen species is limited by a com-
associated with the development of skin cancer. While all renal plex array of antioxidant enzymes, an important group of
transplant recipients should be advised to protect themselves which are the glutathione S-transferases (GSTs). Thesefrom the sun, the identification of transplant patients with a
enzymes are found throughout the animal and plantgenetic predisposition to skin tumors may permit the targeting
kingdom and have been detected in almost all humanof preventative and early intervention strategies to high-risk
individuals. tissues. They protect cells from cytotoxic and carcino-
genic agents by conjugating reactive chemical species to
reduced glutathione, and additionally, some isoenzymes
An increased risk of skin cancer is a well-recognized have intrinsic organic peroxidase activity [11, 12].
complication of renal transplantation, with a prevalence Multiple human GSTs have been isolated with distinct
of 14% 10 years after transplantation and rising to 30 to substrate specificities and catalytic efficiencies. Common
variants have been identified in three of these GST en-
zymes, namely mu (GSTM), pi (GSTP), and theta (GSTT)
Key words: genetic susceptibility, skin tumor, free radical metabolism,
[13, 14]. The most common polymorphism is a largesquamous cell carcinomas, basal cell carcinomas, UV light exposure,
anti-oxidants. deletion of the GSTM1 gene, and 50% of Caucasoid are
homozygous for this variant (GSTM1null) [15]. Addi-Received for publication June 22, 1999
tionally, the GSTM1 gene exhibits a single nucleotideand in revised form May 25, 2000
Accepted for publication May 30, 2000 polymorphism in exon 7 that results in a lysine to aspara-
gine substitution at position 172. These alleles are desig-Ó 2000 by the International Society of Nephrology
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Table 1. Demographic details of renal transplant cohortnated GSTM1A and GSTM1B, respectively, but have
not been associated with any differences in functional Renal transplant cohort N 5 222
activity [15, 16]. Deletion of the GSTT1 locus is also Sex
male 129 58%common, with approximately 20% of Caucasoids being
female 93 42%homozygous for the null allele [17]. Two common single-
Number of transplants
nucleotide polymorphisms have been described in exon 1 168 76%
.1 54 24%5 and exon 6 of the GSTP1 gene, which occur in four
Age at first transplantpossible combinations [18, 19], resulting in variation in
,50 155 70%
enzyme activity and substrate selectivity both in vivo .50 67 30%
Any skin cancer[19] and in vitro [20].
Neither BCC or SCC 174 78%The importance of these enzymes as systemic antioxi-
Either BCC or SCC 48 22%
dants has identified them as prime candidates in cancer SCC 34 15%
BCC 24 11%susceptibility studies [12]. Homozygosity for the null
variant of the GSTM1 gene has been extensively investi-
gated and has been associated with smoking-induced
tumors, among others [21, 22]. In addition, the null phe-
notype of GSTT1 has been associated with colon cancer METHODS
[23] and myelodysplasia [24], and the GSTP1 Val105 Patient cohorts
polymorphism has been associated with an increased risk
This study was approved by the Central Oxford Re-of bladder and testicular cancers [25] and an increased
search Ethics Committee. All renal transplant recipientsrisk of lung cancer [26].
at the Oxford Transplant Center were assessed for theAs these enzymes may be particularly important in
presence or absence of skin tumors by review of clinicaldetoxifying UV irradiation-induced reactive oxygen spe-
and pathological records (C. Bordea, manuscript in prep-cies, their role in skin cancer has also been studied. In
aration), and all patients with lesions suggestive of malig-nonimmunosuppressed individuals, susceptibility to mul-
nancy were reviewed by a dermatologist in a dedicatedtiple BCCs has been associated with the null variant of
transplant dermatology clinic. Patients were included inGSTM1 [17, 27] and also to the null variant of GSTT1
this study if they had received at least one cadaveric[28]. Furthermore, the combination of GSTM1/GSTT1
renal transplant that functioned for more than five years,double null genotype has been shown to be associated
if they received an immunosuppressive protocol that in-with a more intense inflammatory response after UV irra-
cluded cyclosporine A for at least five years, and if DNAdiation than other genotypes [29], supporting an important
prepared from peripheral blood was available. To max-role for these enzymes in free radical metabolism within
imize ethnic homogeneity, all individuals were of Euro-the skin. GSTP polymorphisms have not been studied
pean Caucasoid descent.in human skin disease, but a number of lines of evidence
Two hundred twenty-two patients were available forsupport a role for this enzyme in the etiology of skin
study, and of these, 48 had developed at least one skinmalignancies. It is a major antioxidant in both the epider-
tumor. Demographic details of this cohort are shownmis and the dermis of the skin [30, 31], where it is overex-
in Table 1. Skin tumors were classified by pathologicalpressed in a variety of preneoplastic and neoplastic tis-
criteria into SCC or BCC. Genetic associations weresues [32, 33]. In addition, deletion of the GSTP gene
analyzed in all patients who developed SCC (N 5 34)cluster in mice results in greatly increased susceptibility
and in all patients who developed BCC (N 5 24). Tento toxin-induced benign skin tumors [34]. Thus, there is
individuals were included in both groups as they devel-considerable evidence to support a role for polymor-
oped both SCC and BCC. Clinical details, including num-phisms in these genes in the pathogenesis of skin tumors.
ber of rejection episodes and use of antithymocyte globu-Genetic susceptibility to skin cancers may be particu-
lin, were retrieved from a clinical database. Total timelarly important in immunosuppressed individuals, who
of immunosuppression was calculated by the summationexperience the additional insults of long-term immuno-
of survival of each transplant and was censored at thesuppression and increased susceptibility to HPV infec-
time of diagnosis of the first skin cancer if appropriate.tion. Antioxidant enzymes provide protection against free
radical-mediated damage, and genetically encoded varia-
Genotyping assaystion in enzyme function is likely to play an important role
Polymerase chain reaction with sequence specific prim-in determining susceptibility. This study was designed to
ers (PCR-SSP) assays that use identical amplificationdetermine the association between genetic variation in
and detection conditions for all GST variants were devel-three polymorphic GST genes and the development of
oped. The genetic parameters of both the GSTM1 dele-skin tumors in a well-characterized cohort of long-term
survivors of renal transplantation. tion and the GSTT1 deletion are unknown. PCR primers
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for GSTM1 were therefore designed to amplify specifi-
cally the GSTM1*A or GSTM1*B allele, with allelic
specificity determined by the terminal 39 nucleotide of
the primer. Homozygosity for the null allele was inferred
from absence of both the GSTM1*A and GSTM1*B
amplicon. Primers for GSTT1 were based on previously
published primers that determine the presence or ab-
sence of the GSTT1 gene deletion [35]. Using these prim-
ers, heterozygosity and homozygosity for the presence of
the gene cannot be distinguished. To maximize efficiency,
primers for GSTM1 and GSTT1 were multiplexed within
the same reaction mix [36]. To genotype GSTP1 variants,
an assay was developed that uses both forward and re-
verse allele-specific primers enabling identification of cis/
trans orientation (“PCR haplotyping”) [37]. All reaction
mixes included control primers in order to verify success-
ful amplification. Primers and reaction mix composition
are detailed in Table 2.
DNA extraction, PCR amplification, and gel electro-
phoresis were identical for all assays and have been de-
scribed in previous reports [38]. DNA was extracted from
ethylenediaminetetraacetic acid (EDTA) or trisodium
citrate anticoagulated peripheral blood using a modified
salting-out method [39] and was amplified in 13 mL reac-
tion mixtures consisting of 67 mmol/L Tris base, pH 8.8;
16.6 mmol/L ammonium sulfate; 2 mmol/L magnesium
chloride; 0.01% vol/vol Tween 20; 200 mmol/L of each of
dATP, dTTP, dGTP, and dCTP; between 0.1 and 0.01 mg
DNA; and 0.1875 units of Taq polymerase (Advanced
Biotechnology, London, UK). Primer concentrations were
optimized for each reaction. Reaction mixtures were dis-
pensed under 10 mL of mineral oil (Sigma, UK) in 96-
well PCR plates (Costar, High Wycombe, UK).
DNA samples were amplified in MJ Research PTC-
200 thermal cyclers, and PCR plates were sealed and
dipped in mineral oil to improve plate-to-block contact.
Cycling parameters were as follows: 1 minute at 968C
followed by 5 cycles of 968C for 25 seconds, 708C for 45
seconds and 728C for 45 seconds, followed by 21 cycles
of 968C for 25 seconds, 658C for 50 seconds and 728C for
45 seconds, followed by 4 cycles of 968C for 25 seconds,
558C for 60 seconds, and 728C for 120 seconds. Following
PCR, 5 mL of loading buffer, consisting of 0.25% Orange G,
30% vol/vol glycerol, and 0.5 3 TBE buffer (89 mmol/L
Tris base, 89 mmol/L boric acid, 2 mmol/L EDTA, pH
8.0), were added to each reaction mix. PCR products
were electrophoresed in 1.0% agarose gels containing
10 mg/L ethidium bromide for 30 to 35 minutes at 15
V/cm in 0.5 3 TBE buffer, visualized with UV illumina-
tion, and photographed.
Statistics
Phenotype, genotype, and allele frequencies were
measured for all polymorphisms where appropriate. As-
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table analysis and the Chi-square test, with Yates’ correc-
tion or Fisher’s exact tests where appropriate. Odds ratio
(OR) and the OR 95% confidence interval were also
calculated for significant associations (P , 0.05). Only
significant associations are highlighted in the tables.
RESULTS
The patient cohort comprised 222 long-term survivors
of renal transplantation, of whom 24 had SCC only, 14
had BCC only, and 10 had both SCC and BCC skin
cancers. The duration of immunosuppressive therapy,
male sex, and age at time of first transplant were all
associated with the development of skin cancer, particu-
larly SCC (Table 3). Male sex was also associated with
the development of BCC skin cancers. More than one
rejection episode and the use of antithymocyte globulin
were not associated with incidence of skin cancer.
Analysis of GST polymorphisms demonstrated that
the presence of the GSTP1*C allele was associated with
the occurrence of skin tumors, specifically SCC (Table 4,
P skin tumors 5 0.05, P SCC 5 0.01, OR 3.1). The
presence of the GSTP1*C allele was associated with SCC
when analyzed by genotype, phenotype, or allele fre-
quency. While numbers were small, stratification by de-
mographic criteria, including sex, age at first transplant,
and total time of immunosuppression, revealed no addi-
tional associations. No associations between GST poly-
morphisms and BCC tumors were identified. GSTM1
and GSTT1 genotypes were not associated with the de-
velopment of either SCC or BCC skin tumors, when
analyzed either individually or together (Table 4).
DISCUSSION
Exposure to UV irradiation is the major factor influ-
encing the development of skin tumors in both immuno-
compromised and nonimmunocompromised individuals.
One mechanism by which UV light exerts its effect is
through generation of free radicals within the skin, which
result in oxidative damage. A number of biological sys-
tems have evolved to counter their destructive effects.
These include direct scavengers, metal chelators, and
enzymes that metabolize free radicals and their interme-
diates to nontoxic agents. An important group of antioxi-
dant enzymes are the GSTs, and this study was designed
to investigate whether genetic polymorphisms in these
enzymes predispose to the development of skin tumors
after transplantation.
A balance between several antioxidant enzymes may
be more important than the activity of a single enzyme
alone for overall protective capacity against free radical-
mediated damage [40], and deficiencies in one gene may
be partially compensated for by increased expression of
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we assessed six polymorphisms in three GST genes in valine (GSTP1*C), has been less widely investigated, but
is also likely to cause differential tertiary folding of thethis study using PCR-SSP genotyping assays that employ
identical amplification and detection conditions. All pa- GST pi superhelix and altered enzyme activity [18]. It
is not clear whether association of increased tumor riskrameters, including DNA concentration, buffers, thermal
cycling conditions, and product detection, are identical for with the GSTP1*C allele is directly the result of the
114Val amino acid change, of the combination of 105Valeach polymorphism, and streamlining the methodology in
this way permits highly efficient simultaneous genotyping with 114Val, or of an unidentified linked polymorphism.
The change in amino acid at position 105 alone does notof multiple polymorphisms. The GSTP1 assay has the addi-
tional advantage of formally demonstrating the cis/trans confer susceptibility, as the GSTP1B genotype was not
associated with increased tumor risk.orientation of nucleotide variants in two adjacent exons,
permitting the direct assignment of different alleles.
ConclusionThe study cohort comprised 222 cadaveric renal trans-
plant recipients. We attempted to maximize homogene- These results suggest that genetic variation in enzymes
ity within the patient cohort by including only high-risk involved in free radical metabolism in the skin predis-
individuals: All patients selected for analysis were of pose to skin cancer in long-term survivors of renal trans-
European Caucasoid ethnic origin and had received plantation. Further studies are required to demonstrate
cyclosporine-based immunosuppression for at least five whether this association is unique to transplantation or
years. Duration of immunosuppressive therapy, male renal disease or whether a similar effect operates in other
sex, and age at time of first transplant were all associated groups at high risk of skin cancer, including nonimmuno-
with the development of SCC after renal transplantation, suppressed individuals with heavy sun exposure. Analy-
as previously reported [2, 3]. In addition, a polymorphism sis of larger cohorts will also permit stratification on the
in the GSTP1 gene was associated with the development basis of other genetic and environmental factors known
of SCC skin cancers. No associations were identified to predispose to skin cancer, including skin type, sun
between the development of BCC and any GST poly- exposure, and presence or absence of HPV infection.
morphism. Previous studies have demonstrated a protec- Such a multivariate analysis is essential to estimate accu-
tive association of the GSTM1*A/*B genotype with both rately the contribution of GST polymorphisms to skin
single [27] and multiple BCCs [17, 27, 28] and have found cancer susceptibility.
the GSTM1null genotype to be associated with skin tu- While all renal transplant recipients, whatever their
mors of more than one histologic type [27]. However, genotype, should be advised to protect themselves from
the size of our study precluded detailed analysis of fac- the sun [6, 43], identification of patients with a genetic
tors such as number or site of tumors or the occurrence predisposition to skin tumors will permit the targeting
of both SCCs and BCCs. of preventative and early intervention strategies. These
The enzyme GSTP1 is widely expressed in human may include regular dermatological review, prompt sur-
tissues, including the skin. It may be an important media- gical excision of suspicious lesions, and possibly early
tor of skin cancer development, as evidenced by the aggressive therapy with agents such as retinoids [44]. In
finding that GSTP null transgenic mice are particularly addition, evidence that genetic variability in free radical-
susceptible to skin papillomas [34], and the association metabolizing enzymes influences individual susceptibil-
of GSTP1 polymorphisms with susceptibility to several ity to sun-associated cancers provides further under-
cancers, including bladder [25], testicular [25], and head standing of the biological effects of UV irradiation.
and neck tumors [41]. The mechanism by which the
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